Avidity Biosciences Inc. (RNA)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Beats Revenue Estimates
Avidity Biosciences, Inc. (RNA) came out with a quarterly loss of $1.27 per share versus the Zacks Consensus Estimate of a loss of $1.05. This compares to a loss of $0.65 per share a year ago.
Analysts Estimate Avidity Biosciences, Inc. (RNA) to Report a Decline in Earnings: What to Look Out for
Avidity Biosciences (RNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Avidity Biosciences (RNA) Moves 42.4% Higher: Will This Strength Last?
Avidity Biosciences (RNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Avidity Biosciences, Inc. (RNA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Avidity Biosciences, Inc. (NASDAQ:RNA ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 1:50 PM EDT Company Participants Kathleen Gallagher - Chief Program Officer Michael MacLean - Chief Financial Officer Katja Lange - Senior VP & Chief Business Officer Presentation Unknown Analyst Good afternoon. Thank you for coming to the Morgan Stanley Healthcare Conference.
Avidity Biosciences, Inc. (RNA) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Avidity Biosciences, Inc. (NASDAQ:RNA ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 12:45 PM EDT Company Participants Michael MacLean - Chief Financial Officer Kathleen Gallagher - Chief Program Officer Conference Call Participants Yanan Zhu - Wells Fargo Securities, LLC, Research Division Presentation Yanan Zhu Senior Equity Analyst Great. Thanks, everyone, for being here.
RNA Stock Moves More Than 30% in a Week: What's Driving This Rally?
Avidity Biosciences surges 36% on reports that Novartis may eye a deal, with talks said to be early and interest from other suitors possible.
Avidity Biosciences, Inc. (RNA) Reports Q1 Loss, Misses Revenue Estimates
Avidity Biosciences, Inc. (RNA) came out with a quarterly loss of $0.90 per share versus the Zacks Consensus Estimate of a loss of $0.88. This compares to loss of $0.79 per share a year ago.
Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock?
Avidity Biosciences (RNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Tops Revenue Estimates
Avidity Biosciences, Inc. (RNA) came out with a quarterly loss of $0.80 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $0.79 per share a year ago.
Avidity Biosciences Advances With FDA Clearance And Promising Data For Rare Diseases
Avidity Biosciences' AOC platform targets genetic diseases by combining monoclonal antibodies with oligonucleotide therapies, overcoming traditional delivery limitations. Del-brax (AOC 1020) for FSHD showed a 50% reduction in DUX4 gene expression, positioning it as a potential best-in-class therapy. Del-desiran (AOC 1001) for DM1 cleared the FDA's clinical hold, enabling progression to Phase 3 HARBOR trials with favorable regulatory designations.
RNA Stock Hits Record High on Entering the Cardiac Disease Space
Avidity Biosciences expands its pipeline to include two new drugs targeting rare genetic cardiomyopathies.
Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' News
Shares of Avidity Biosciences surged to a record high Wednesday after the company showed its hand in the cardiovascular space. The post Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' News appeared first on Investor's Business Daily.
